Hepatocellular carcinoma in viral hepatitis: Improving standard therapy

Best Practice and Research: Clinical Gastroenterology

Volumn 22, Issue 6, 2008, Pages 1137-1151

  Masuzaki, Ryota ^a   Yoshida, Haruhiko ^a   Tateishi, Ryosuke ^a   Shiina, Shuichiro ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Hepatocellular carcinoma; Prevention; Radio frequency ablation

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CONTRAST MEDIUM; DECARBOXYPROTHROMBIN; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; RIBAVIRIN; SORAFENIB; UFT;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; CANCER INCIDENCE; CANCER INHIBITION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EARLY DIAGNOSIS; EARLY INTERVENTION; ECHOGRAPHY; ERADICATION THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER ANGIOGRAPHY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; RADIOFREQUENCY ABLATION; SCREENING TEST; SECONDARY PREVENTION; TREATMENT OUTCOME; VACCINATION; VIRUS CARCINOGENESIS; VIRUS HEPATITIS; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COMORBIDITY; DRUG DELIVERY SYSTEMS; HEPATECTOMY; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PRIMARY PREVENTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 58949103878     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2008.11.005     Document Type: Article

References (84)

1. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 15 (1992) 948-963
2. Sherlock S. Viruses and hepatocellular carcinoma. Gut 35 (1994) 828-832
3. Omata M., Ashcavai M., Liew C.T., and Peters R.L. Hepatocellular carcinoma in the U.S.A., etiologic considerations. Localization of hepatitis B antigens. Gastroenterology 76 (1979) 279-287
4. Bosch F.X., Ribes J., and Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 19 (1999) 271-285
5. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
6. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
7. Taylor-Robinson S.D., Foster G.R., Arora S., et al. Increase in primary liver cancer in the UK, 1979-94. Lancet 350 (1997) 1142-1143
8. Stroffolini T., Andreone P., Andriulli A., et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 29 (1998) 944-952
9. Kew M.C., Yu M.C., Kedda M.A., et al. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 112 (1997) 184-187
10. Pybus O.G., Charleston M.A., Gupta S., et al. The epidemic behavior of the hepatitis C virus. Science 292 (2001) 2323-2325
11. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
12. Frank C., Mohamed M.K., Strickland G.T., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355 (2000) 887-891
13. Okuda K., Fujimoto I., Hanai A., and Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 47 (1987) 4967-4972
14. Omata M., Yoshida H., and Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 3 (2005) S141-S143
15. Tanaka Y., Hanada K., Mizokami M., et al. Inaugural article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 99 (2002) 15584-15589
16. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
17. Simonetti R.G., Camma C., Fiorello F., et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 116 (1992) 97-102
18. Colombo M., de Franchis R., Del Ninno E., et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325 (1991) 675-680
19. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 (1999) 174-181
20. Nishiguchi S., Kuroki T., Nakatani S., et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346 (1995) 1051-1055
21. Shiratori Y., Imazeki F., Moriyama M., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132 (2000) 517-524
22. Sakon M., Umeshita K., Nagano H., et al. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 135 (2000) 1456-1459
23. Kubo S., Nishiguchi S., Hirohashi K., et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134 (2001) 963-967
24. Shiratori Y., Shiina S., Teratani T., et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138 (2003) 299-306
25. Chang M.H., Shau W.Y., Chen C.J., et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 284 (2000) 3040-3042
26. Chen P.J., and Chen D.S. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin Liver Dis 19 (1999) 253-262
27. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
28. Minami Y., Kudo M., Chung H., et al. Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial. Am J Roentgenol 188 (2007) 489-494
29. Morimoto M., Shirato K., Sugimori K., et al. Contrast-enhanced harmonic gray-scale sonographic-histologic correlation of the therapeutic effects of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Am J Roentgenol 181 (2003) 65-69
30. Coin C.G., and Chan Y.S. Computed tomographic arteriography. J Comput Assist Tomogr 1 (1977) 165-168
31. Taketa K., Sekiya C., Namiki M., et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 99 (1990) 508-518
32. van Staden L., Bukofzer S., Kew M.C., and Savage N. Differential lectin reactivities of alpha-fetoprotein in hepatocellular carcinoma: diagnostic value when serum alpha-fetoprotein levels are slightly raised. J Gastroenterol Hepatol 7 (1992) 260-265
33. Yamashita F., Tanaka M., Satomura S., and Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 111 (1996) 996-1001
34. Tateishi R., Shiina S., Yoshida H., et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 44 (2006) 1518-1527
35. Izuno K., Fujiyama S., Yamasaki K., et al. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology 42 (1995) 387-393
36. Shimada M., Takenaka K., Fujiwara Y., et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 78 (1996) 2094-2100
37. Aoyagi Y., Oguro M., Yanagi M., et al. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 77 (1996) 1781-1786
38. Koike Y., Shiratori Y., Sato S., et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 91 (2001) 561-569
39. Torzilli G., Makuuchi M., Inoue K., et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 134 (1999) 984-992
40. Bruix J., Castells A., Bosch J., et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111 (1996) 1018-1022
41. Llovet J.M., Schwartz M., and Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25 (2005) 181-200
42. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
43. Balsells J., Charco R., Lazaro J.L., et al. Resection of hepatocellular carcinoma in patients with cirrhosis. Br J Surg 83 (1996) 758-761
44. Iwatsuki S., Starzl T.E., Sheahan D.G., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214 (1991) 221-228 discussion 228-229
45. Pichlmayr R., Weimann A., Oldhafer K.J., et al. Appraisal of transplantation for malignant tumours of the liver with special reference to early stage hepatocellular carcinoma. Eur J Surg Oncol 24 (1998) 60-67
46. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
47. Llovet J.M., Fuster J., and Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30 (1999) 1434-1440
48. Trotter J.F., Wachs M., Everson G.T., and Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 346 (2002) 1074-1082
49. Kawasaki S. Living-donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 49 (2002) 53-55
50. Steinmuller T., Pascher A., Sauer I., et al. Living-donation liver transplantation for hepatocellular carcinoma: time to drop the limitations?. Transplant Proc 34 (2002) 2263-2264
51. Gondolesi G.E., Roayaie S., Munoz L., et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 239 (2004) 142-149
52. Todo S., and Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 240 (2004) 451-459 discussion 459-461
53. Sugawara Y., Tamura S., and Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 25 (2007) 310-312
54. Sugawara Y., and Makuuchi M. Advances in adult living donor liver transplantation: a review based on reports from the 10th anniversary of the adult-to-adult living donor liver transplantation meeting in Tokyo. Liver Transpl 10 (2004) 715-720
55. Sarasin F.P., Majno P.E., Llovet J.M., et al. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 33 (2001) 1073-1079
56. Livraghi T., Festi D., Monti F., et al. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology 161 (1986) 309-312
57. Shiina S., Yasuda H., Muto H., et al. Percutaneous ethanol injection in the treatment of liver neoplasms. Am J Roentgenol 149 (1987) 949-952
58. Rossi S., Di Stasi M., Buscarini E., et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1 (1995) 73-81
59. Livraghi T., Goldberg S.N., Lazzaroni S., et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210 (1999) 655-661
60. Shiina S., Teratani T., Obi S., et al. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 62 Suppl. 1 (2002) 64-68
61. Omata M., Tateishi R., Yoshida H., and Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 127 (2004) S159-S166
62. Lin S.M., Lin C.J., Lin C.C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 127 (2004) 1714-1723
63. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 (2005) 122-130
64. Tateishi R., Shiina S., Teratani T., et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103 (2005) 1201-1209
65. Teratani T., Yoshida H., Shiina S., et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 43 (2006) 1101-1108
66. Kondo Y., Yoshida H., Shiina S., et al. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract. Br J Surg 93 (2006) 1277-1282
67. Camma C., Schepis F., Orlando A., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 (2002) 47-54
68. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
69. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
70. Patt Y.Z., Hassan M.M., Aguayo A., et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101 (2004) 578-586
71. Lencioni M., Falcone A., Allegrini G., et al. Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. Oncology 59 (2000) 204-209
72. Chow P.K., Tai B.C., Tan C.K., et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 36 (2002) 1221-1226
73. Llovet J.M., Ruff P., Tassopoulos N., et al. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 37 (2001) 1352-1358
74. Obi S., Yoshida H., Toune R., et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106 (2006) 1990-1997
75. Matsuo M., Sakurai H., and Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2 (2003) 557-561
76. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23 (2005) 6657-6663
77. Thomas M.B., Chadha R., Glover K., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110 (2007) 1059-1067
78. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 1898-1903
79. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
80. Sasaki Y., Yamada T., Tanaka H., et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 244 (2006) 771-780
81. Poon R.T., Fan S.T., Lo C.M., et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235 (2002) 373-382
82. Hasegawa K., Takayama T., Ijichi M., et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 44 (2006) 891-895
83. Muto Y., Moriwaki H., Ninomiya M., et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334 (1996) 1561-1567
84. Habu D., Shiomi S., Tamori A., et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 292 (2004) 358-361